Sign In
Buy MRNA
$47.44
-4.15 (-8.04%)
At Close: Jun 05, 2026
Just Say No to Drugs: 3 Pharma Stocks to Avoid
10:30am, Wednesday, 08'th May 2024
From its stellar performance in 2021 to deflating in 2022, the biotech sector continued its stagnation into 2023, highlighting some pharma stocks to avoid. Year-to-date, the S&P Biotechnology Select I
MRNA, GILD: What to Watch in Biotech Stocks
11:53am, Monday, 06'th May 2024
Fiscal discipline is important going forward, notes Hartaj Singh on Moderna (MRNA). He discusses biotech stocks Moderna and Gilead Sciences (GILD).
Largest U.S. Pension Sold Verizon, Disney, and Peloton Stock. It Bought Moderna.
03:00am, Sunday, 05'th May 2024
Calpers slashed investments in Verizon, Disney, and Peloton stock, and doubled down on Moderna shares in the first quarter.
Shhh! 3 Secret Pharma Stocks Flying Below Wall Street's Radar
06:15am, Friday, 03'rd May 2024
Pharma stocks and massive potential go hand in hand. With devastating diseases like cancer, diabetes and heart disease still far from finding a cure, drugs that treat these conditions often command ex
Why Moderna Stock Blasted 13% Higher Today
06:36pm, Thursday, 02'nd May 2024
Investors and analysts broadly expected the biotech's results to wither in the first quarter, and they were right. Still, it did better than many anticipated.
Moderna (MRNA) CFO on Earnings & Outlook
04:31pm, Thursday, 02'nd May 2024
Moderna's (MRNA) adjusted EPS came in at -$3.07 versus an estimated -$3.59 and revenue came in at $167.00M versus an estimated $124.74M. CFO Jamey Mock joins Oliver Renick to discuss Moderna's 1Q earn
Moderna CEO talks Q1 earnings, Brazil COVID vaccine, and cancer treatment markets
01:48pm, Thursday, 02'nd May 2024
Shares of pharmaceutical company Moderna (MRNA) are on the rise despite first quarter losses. Moderna CEO Stéphane Bancel tells Yahoo Finance Senior Reporter Anjalee Khemlani that the company is busy
Moderna (MRNA) Q1 Earnings Beat Estimates, Revenues Down Y/Y
12:16pm, Thursday, 02'nd May 2024
Moderna (MRNA) beats expectations for both earnings and sales. Management reiterates guidance to record around $4 billion from product sales in 2024.
2 Biotech Stocks To Watch Today Amid Earnings
10:18am, Thursday, 02'nd May 2024
Here are two biotech stocks to watch after their recent earnings report.
Moderna (MRNA) Reports Q1 Loss, Tops Revenue Estimates
08:40am, Thursday, 02'nd May 2024
Moderna (MRNA) came out with a quarterly loss of $3.07 per share versus the Zacks Consensus Estimate of a loss of $3.59. This compares to earnings of $0.19 per share a year ago.
Moderna CEO Stephane Bancel on Q1 results: The vaccine platform is coming together very nicely
08:15am, Thursday, 02'nd May 2024
Moderna CEO Stephane Bancel joins 'Squawk Box' to discuss the company's quarterly earnings results, which posted a narrower-than-expected loss for the first quarter as the company's cost-cutting effor
Moderna Q1 earnings: lower-than-expected loss of $1.18 billion sets tone for vaccine launch
07:00am, Thursday, 02'nd May 2024
Moderna Inc (NASDAQ: MRNA) reported a narrower-than-expected loss for the first quarter of the year, setting a positive tone as it prepares to launch its second product in the U.S. market later this y
Highly ranked manager who bet on Mag 7 giants looks to these second-order winners from AI
06:48am, Thursday, 02'nd May 2024
Large-cap growth funds have been in the sweet spot for a few years now, thanks to megacap tech holdings.
Moderna loses less than expected as Covid vaccine sales beat estimates, cost cuts take hold
06:35am, Thursday, 02'nd May 2024
The company reiterated its full-year 2024 sales guidance of roughly $4 billion, which includes revenue from the expected launch of its RSV vaccine.
Moderna quarterly sales beat expectations but plummet from previous year
06:33am, Thursday, 02'nd May 2024
Moderna on Thursday reported quarterly revenue that beat Wall Street estimates but came in dramatically lower than the previous year when demand for COVID-19 vaccines was higher.
